 |
|
Drug compound leads to death of ovarian cancer cells resistant to chemotherapy
April 18, 2008In a discovery that may be useful for maintaining remission in chemo-resistant ovarian cancer, Yale scientists report that pre-clinical studies have shown the drug compound NV-128 can induce the death of ovarian cancer cells by halting the activation of a protein pathway called mTOR.
Gil Mor, M.D., associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine, and associate research scientist Ayesha Alvero, M.D. presented the data April 15 during an oral presentation at the annual meeting of the American Association for Cancer Research.
In cancer cells, mTOR signals enhance tumor growth and may be associated with resistance to conventional therapies. Inhibition of mTOR could shut down many of these survival pathways, including proteins that protect the mitochondria of cancer cells.
NV-128, developed by Novogen Limited, holds promise as a more targeted therapy for ovarian cancer because it works differently from traditional therapies that are dependent on enzymes known as caspases to trigger cell death. Therapies using caspases to kill cancer cells can be ineffective in chemo-resistant cancer cells due to mutations that short-circuit signals that trigger cancer cell death.
"We consider that the capacity of NV-128 to trigger caspase-independent cell death, in otherwise chemoresistant ovarian cancer cells, opens new possibilities for the use of NV-128 as a potential addition to conventional chemotherapy targeting ovarian cancer cells," said Mor.
In the context of developing therapies for late stage ovarian cancer, Mor said, the finding may be "a key step to the development of alternative targeted therapy for patients with cancer recurrence."
Yale University
NV-128, developed by Novogen Limited, holds promise as a more targeted therapy for ovarian cancer because it works differently from traditional therapies that are dependent on enzymes known as caspases to trigger cell death. Therapies using caspases to kill cancer cells can be ineffective in chemo-resistant cancer cells due to mutations that short-circuit signals that trigger cancer cell death.
"We consider that the capacity of NV-128 to trigger caspase-independent cell death, in otherwise chemoresistant ovarian cancer cells, opens new possibilities for the use of NV-128 as a potential addition to conventional chemotherapy targeting ovarian cancer cells," said Mor.
In the context of developing therapies for late stage ovarian cancer, Mor said, the finding may be "a key step to the development of alternative targeted therapy for patients with cancer recurrence."
Yale University
Ovarian Cancer Current Events and Ovarian Cancer News RSSDisease diagnosis in just 15 minutes
Testing for diseases such as cancer and multiple sclerosis could soon be as simple as using a pregnancy testing kit.
Bio-imaging mass spectrometry techniques reveal molecular details about complex systems
Understanding biology at the systems level is difficult, especially when studying complex specimens like tissue slices or communities of organisms in a biofilm. Scientists must be able to identify, quantify and locate the molecules present in the samples.
Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
A research team, led by investigators at the Department of Surgery at Jefferson Medical College of Thomas Jefferson University and the Kimmel Cancer Center at Jefferson, has achieved a substantial "kill" of pancreatic cancer cells by using nanoparticles to successfully deliver a deadly diphtheria toxin gene.
Promising new treatment option for women with recurrent ovarian cancer
Combining the new drug trabectedin with pegylated liposomal doxorubicin provides clinical benefit to women with relapsed ovarian cancer, according to new results presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.
Risk of breast cancer mutations underestimated for Asian women, Stanford study shows
Oncologist Allison Kurian, MD, and her colleagues at the Stanford University School of Medicine were perplexed. Computer models designed to identify women who might have dangerous genetic mutations that increase their risk of breast and ovarian cancer worked well for white women. But they seemed to be less reliable for another ethnic group.
Cryopreservation techniques bring hopes for women cancer victims and endangered species
Emerging cryopreservation techniques are increasing hope of restoring fertility for women after diseases such as ovarian cancer that lead to destruction of reproductive tissue.
Study challenges routine use of MRI scans to evaluate breast cancer
A new study suggests women with newly-diagnosed breast cancer who receive an MRI after their diagnosis face delays in starting treatment and are more likely to receive a mastectomy.
Variation of normal protein could be key to resistance to common cancer drug
Researchers at the Moores Cancer Center at the University of California, San Diego (UC SD) in La Jolla have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug.
New method to overcome multiple drug resistant diseases developed by Stanford researchers
Many drugs once considered Charles Atlases of the pharmaceutical realm have been reduced to the therapeutic equivalent of 97-pound weaklings as the diseases they once dispatched with ease have developed resistance to them.
How chemo kills tumours: research to reduce side effects
Dr Stephen Taylor and Karen Gascoigne at the University's Faculty of Life Sciences have taken a new systematic approach to studying anti-mitotic drugs, which are used extensively for breast or ovarian cancer in the UK.
More Ovarian Cancer Current Events and Ovarian Cancer News Articles
 | A Guide to Survivorship for Women with Ovarian Cancer (A Johns Hopkins Press Health Book) by F. J. Montz, Robert E. Bristow This comprehensive guide to ovarian cancer offers a wealth of information to ease the physical, emotional, and psychic suffering of women with the disease. The authors -- two Johns Hopkins gynecologic oncologists and a gynecologic-oncology clinical nurse -- put particular emphasis on the concept of "survivorship," or living life well in the face of daunting uncertainties. They stress the... |
 | Ovarian Cancer Journeys: Survivors Share Their Stories To Help Others by Ayala Miron "All of the research has reinforced that ovarian cancer is not a silent disease as was once thought and as is shown quite eloquently in this collection of stories.... The value of this collection of stories is that it helps raise awareness about symptoms, need for patient persistence, and the importance of being treated by a gynecologic oncologist." Barbara A. Goff, MD Professor and... |
 | Beating Ovarian Cancer: How To Overcome The Odds And Reclaim Your Life by Chris Bledy A diagnosis of Ovarian Cancer does not have to be a death sentence. Recent advances in medicine have made this once incurable disease treatable and manageable. You can beat advanced and even recurring, ovarian cancer. Simple but significant lifestyle changes can produce big results when it comes to... |
 | Ovarian Cancer (Patient-Centered Guides) by Kristine Conner, Lauren Langford This unique guide for ovarian cancer gives women crucial medical information to improve the chance for lengthy remission and cure, as well as emotional support for the journey. Although many ovarian cancers are discovered after they have spread, having information about surgery and best practices can be life-saving. For example, choosing a surgeon from the new specialty of gynecologic oncology... |
 | Gilda's Disease: Sharing Personal Experiences and a Medical Perspective on Ovarian Cancer by Steven Piver The first book on ovarian cancer for the general reader, this is a comprehensive, compassionate look at a disease millions of people first became aware of with the tragic death of comedienne Gilda Radner in 1989. Dr. Piver, a leading cancer surgeon, discusses the causes of ovarian cancer, preventative measures, classic signs and symptoms, diagnostic tests and genetic screening, the different... |
 | 100 Questions & Answers About Ovarian Cancer, Second Edition by Don S. Dizon Whether you're a newly diagnosed ovarian cancer patient, a survivor, or a friend or relative of either, this completely updated second edition gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. Written by a gynecologic oncologist and a gynecologic surgeon, with actual patient commentary, ... |
 | A Feather in My Wig: Ovarian Cancer Cured, Seventeen Years and Going Strong! by Barbara R. Van Billiard With sensitivity and with humor, Barbara Van Billiard sets down the facts of her struggle and outlines the steps she took to deal with surgeries and chemotherapy. Her use of, and explanation, of various mind-body techniques, such as imagery and meditation, are a thought provoking approach that any cancer patient could use to help with life threatening... |
 | 100 Q&A About Ovarian Cancer by Don S. Dizon Covers a wide range of topics, including ovarian cancer; risk factors, diagnosis, treatment and side effects; and strategies for coping with emotional and healthcare... |
 | Ovarian Cancer: State of the Art and Future Directions in Translational Research (Advances in Experimental Medicine and Biology) (Advances in Experimental Medicine and Biology) Aegean Conferences is an independent, nonprofit, educational organization directed and managed by the scientific community. The board is made up of nine researchers/scientists in various disciplines from Harvard, Brown, University of Pennsylvania, UCSD, Princeton, Biovista and the Foundation for Biomedical Research Academy of Athens. The board both invites and approves unsolicited proposals for... |
| Understanding Ovarian Cancer Anatomical Chart This chart provides a textual and visual overview of ovarian cancer, as well as the stages of... |
| © 2008 BrightSurf.com |